Australian public assessment report for Rituximab

The sponsor is currently conducting a multi-centre (US-based), prospective, observational study designed to follow 100 RTX-treated patients with GPA or MPA for a maximum of 4 years (Study WA27893). An interim analysis will be performed when all patients are enrolled and approximately 50% of the estimated total patient-year exposure data (327 ... ................
................